ImmunityBio EBIT

The latest EBIT for IBRX is $-370M as of June 2026. That compares with $-230M in the prior-year period — down 63.1% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside ImmunityBio's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBRX's EBIT moved from $-230M to $-370M — a 63.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ImmunityBio's operating scale or balance-sheet position.

Against Healthcare companies, IBRX currently prints $-370M for EBIT, while the sector average sits near $22B. That is roughly 101.7% below the sector mean. Large gaps often invite a closer look at ImmunityBio's growth, margins, and balance sheet.

A EBIT figure of $-370M for IBRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting IBRX's EBIT ($-370M), review year-over-year change from $-230M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.